Causes of Death and Risk Factors for Mortality among HIV-Infected Patients Receiving Antiretroviral Therapy in Korea.
10.3346/jkms.2013.28.7.990
- Author:
Sun Hee LEE
1
;
Kye Hyung KIM
;
Seung Geun LEE
;
Heerim CHO
;
Dong Hwan CHEN
;
Joo Seop CHUNG
;
Ihm Soo KWAK
;
Goon Jae CHO
Author Information
1. Deparment of Internal Medicine, Pusan National University School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea. zzanmery@gmail.com
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
HIV;
Antiretroviral Therapy;
Mortality;
Cause of Death;
Risk Factors;
Loss to Follow-up;
Retention in Care;
Visit Constancy
- MeSH:
Anti-Retroviral Agents/*adverse effects/*therapeutic use;
Antiretroviral Therapy, Highly Active/adverse effects;
CD4 Lymphocyte Count;
Cause of Death;
Coinfection;
Female;
HIV Infections/*drug therapy/*mortality/virology;
Humans;
Male;
Middle Aged;
Republic of Korea;
Retrospective Studies;
Risk Factors;
Treatment Outcome
- From:Journal of Korean Medical Science
2013;28(7):990-997
- CountryRepublic of Korea
- Language:English
-
Abstract:
A retrospective study was conducted to determine the mortality, causes and risk factors for death among HIV-infected patients receiving antiretroviral therapy (ART) in Korea. The outcomes were determined by time periods, during the first year of ART and during 1-5 yr after ART initiation, respectively. Patients lost to follow-up were traced to ascertain survival status. Among 327 patients initiating ART during 1998-2006, 68 patients (20.8%) died during 5-yr follow-up periods. Mortality rate per 100 person-years was 8.69 (95% confidence interval, 5.68-12.73) during the first year of ART, which was higher than 4.13 (95% confidence interval, 2.98-5.59) during 1-5 yr after ART. Tuberculosis was the most common cause of death in both periods (30.8% within the first year of ART and 16.7% during 1-5 yr after ART). During the first year of ART, clinical category B and C at ART initiation, and underlying malignancy were significant risk factors for mortality. Between 1 and 5 yr after ART initiation, CD4 cell count < or = 50 cells/microL at ART initiation, hepatitis B virus co-infection, and visit constancy < or = 50% were significant risk factors for death. This suggests that different strategies to reduce mortality according to the time period after ART initiation are needed.
